Pharmacogenomics study of telmisartan and indapamide in patients with essential hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-12002769

Enrollment

Unknown

Registered

2012-11-21

Start date

2008-01-14

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

telmisartan group:telmisartan

indapamide group:ndapamide

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with primary hypertension; (2) age >=18.

Exclusion criteria

Exclusion criteria: Secondary hypertension; pregnant or lactating were excluded from this study

Design outcomes

Primary

Measure	Time frame
Blood pressure;related gene;	—

Countries

China

Contacts

Public ContactWei Zhang

yjsd2003@163.com+86 0731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026